Physician profile
Alejandro Pena
NPI 1093151888
$10,907.78
in general payments reported to CMS, 2019-2025
40 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $325 · 2021: $830 · 2022: $988 · 2023: $3,212 · 2024: $3,582 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166 · Travel and Lodging: $3,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,166.09 |
| Travel and Lodging | $3,238.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,313.37 | 2023-2024 | Pascal, Evoque |
| Abbott Laboratories | $1,459.94 | 2019-2025 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $822.30 | 2020-2025 | |
| Pfizer INC. | $629.25 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $541.91 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $504.82 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $429.68 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $423.10 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $415.74 | 2021-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.34 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $335.99 | 2019-2025 | Watchman Flx, Resonate El Icd Vr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.36 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $142.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $134.61 | 2021-2025 | Amvuttra |
| Medtronic Vascular, INC. | $113.74 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $113.12 | 2020-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $105.48 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $84.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $76.39 | 2023-2025 | Evkeeza |
| Medtronic, INC. | $73.83 | 2022-2024 | Apollotm |
| Philips North America LLC | $54.04 | 2022-2025 | Extended Holter |
| Lexicon Pharmaceuticals, INC. | $53.43 | 2023-2024 | Inpefa |
| Penumbra, INC. | $50.11 | 2025 | Benchmark |
| Astellas Pharma US INC | $47.12 | 2019-2020 | |
| Cvrx, INC. | $37.45 | 2021-2024 | Barostim Neo System |
| Abiomed | $31.56 | 2025 | |
| United Therapeutics Corporation | $30.49 | 2025 | Tyvaso |
| Daiichi Sankyo INC. | $30.17 | 2020-2022 | |
| Scpharmaceuticals INC. | $29.43 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $27.38 | 2021 | |
| Endotronix, INC. | $26.74 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Impulse Dynamics (USA) INC. | $25.56 | 2022 | |
| Bridgebio Pharma, INC. | $22.98 | 2025 | Attruby |
| Stryker Corporation | $20.36 | 2025 | Clottriever Bold Catheter |
| Glaxosmithkline, LLC. | $19.35 | 2025 | Shingrix |
| Atricure, INC. | $18.22 | 2024 | |
| Eisai INC. | $17.74 | 2019 | |
| Biosense Webster, INC. | $15.36 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.04 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $13.64 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.